1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
0
Active Trials
1
Rare Diseases
across 2 areas
0
News (30d)
Quiet
CERo Therapeutics Holdings, Inc. is a company with 1 orphan drug designation across 1 rare disease.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| acute myeloid leukemia | autologous preparation of CD3+ T cells transduced with CTX1236-LV lentivirus encoding a chimeric engulfment receptor (CER), which combines the extracellular phagocytic domain of TIM-4 with intracellular signaling domains CD28, CD3 zeta, and Toll-like receptor 2 (TLR2)/TIR/interleukin (TIR) | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/1
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/1
candidate diseases
0
avg importance: 0
0
affecting portfolio